Preclinical and preliminary clinical evidence indicates that radiolabeled somatostatin (sst)
receptor antagonists perform better than agonists in detecting neuroendocrine tumors …

Radiolabeled somatostatin (sst) receptor agonists are integral to the diagnosis of
gastroenteropancreatic neuroendocrine tumors (NETs), but detection rates, especially of …

Purpose: Abundant expression of somatostatin receptors (sst) is a characteristic of
neuroendocrine tumors (NET). Thus, radiolabeled somatostatin analogs have emerged as …

Physiologically increased pancreatic uptake at the head/uncinate process is observed in
more than one-third of patients after injection of one of the three 68 Ga-labelled octreotide …

Somatostatin receptor imaging (SRI) with [111In-DTPA0] octreotide has proven its role in the
diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). Newer …

Purpose Somatostatin receptor antagonists have shown promise for imaging
neuroendocrine tumors (NETs) in preclinical studies, but clinical data is still very limited. In …

Somatostatin receptor PET tracers such as [68Ga-DOTA, 1-Nal3]-octreotide (68Ga-
DOTANOC) and [68Ga-DOTA, Tyr3]-octreotate (68Ga-DOTATATE) have shown promising …

68Ga-NODAGA-LM3 (where LM3 is p-Cl-Phe-cyclo (d-Cys-Tyr-d-4-amino-Phe (carbamoyl)-
Lys-Thr-Cys) d-Tyr-NH2) and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 …

The trend to inform personalized molecular radiotherapy with molecular imaging
diagnostics, a concept referred to as theranostics, has transformed the field of nuclear …

Background Peptide receptor radionuclide therapy (PRRT) with 177 Lu-[DOTA 0, Tyr 3]
octreotate (177 Lu-octreotate) is generally performed using a fixed activity of 7.4 GBq (200 …